Frontiers in Immunology (Oct 2022)
Case Report: Chronic hepatitis E in a hematopoietic stem cell transplant recipient: The first report of hepatitis E virus genotype 4 causing chronic infection in a non-solid organ recipient
- Zihao Chen,
- Junfeng Wei,
- Li Jiang,
- Dong Ying,
- Dong Ying,
- Weikun Tian,
- Weikun Tian,
- Mengyang Zhang,
- Guiping Wen,
- Siling Wang,
- Chang Liu,
- Yingbin Wang,
- Yingbin Wang,
- Ting Wu,
- Ting Wu,
- Zimin Tang,
- Zimin Tang,
- Zizheng Zheng,
- Zizheng Zheng,
- Li Yan,
- Ningshao Xia,
- Ningshao Xia,
- Ningshao Xia,
- Ningshao Xia
Affiliations
- Zihao Chen
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China
- Junfeng Wei
- Department of Infectious Diseases, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, China
- Li Jiang
- Department of Hematology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, China
- Dong Ying
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China
- Dong Ying
- School of Life Sciences, Xiamen University, Xiamen, China
- Weikun Tian
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China
- Weikun Tian
- School of Life Sciences, Xiamen University, Xiamen, China
- Mengyang Zhang
- Department of Pathology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, China
- Guiping Wen
- United Diagnostic and Research Center for Clinical Genetics, Women and Children’s Hospital, School of Medicine and School of Public Health, Xiamen University, Xiamen, China
- Siling Wang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China
- Chang Liu
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China
- Yingbin Wang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China
- Yingbin Wang
- Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, China
- Ting Wu
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China
- Ting Wu
- Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, China
- Zimin Tang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China
- Zimin Tang
- Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, China
- Zizheng Zheng
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China
- Zizheng Zheng
- Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, China
- Li Yan
- Department of Severe Hepatology, Shanghai Public Health Clinical Centre, Fudan University, Shanghai, China
- Ningshao Xia
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China
- Ningshao Xia
- School of Life Sciences, Xiamen University, Xiamen, China
- Ningshao Xia
- Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, China
- Ningshao Xia
- Research Unit of Frontier Technology of Structural Vaccinology, Chinese Academy of Medical Sciences, Xiamen, China
- DOI
- https://doi.org/10.3389/fimmu.2022.954697
- Journal volume & issue
-
Vol. 13
Abstract
Hepatitis E virus (HEV) is one of the most important public health issues around the world, and chronic HEV infection has been reported in immunosuppressed individuals. This study reported a male case, with very severe aplastic anemia (AA), who developed chronic hepatitis E after hematopoietic stem cell transplantation (HSCT). Abnormal alanine aminotransferase (ALT) appeared after HSCT and persisted for twenty-nine months. The case was seropositive for anti-HEV IgG and IgM after HSCT. Twenty-two months after HSCT, HEV RNA and antigen (Ag) testing were positive and persisted for five and seven months, respectively. Positive stains of HEV Ag were present in a liver biopsy sample. HEV Ag was present in bone marrow. The individual rapidly developed liver cirrhosis and was rescued by a regimen of oral ribavirin. These factors suggested there is a risk of HEV infection in HSCT recipients.
Keywords
- hepatitis E virus
- chronic hepatitis
- hematopoietic stem cells transplantation
- cirrhosis
- aplastic anemia
